A leading provider of real-time technologies for networking solutions and medical laboratory systems.
19-Feb-2018 – 24.5p – £98.8m – PER 340.3
Trading Update For The 12 Months To End December 2017 – Expected to be ahead of market expectations. Revenue of $106m (up 17%), EBITDA of $7m (benefit of $5.6m from property sale) versus $2.8m last time.
I am just not interested here for a number of reasons including location, no real profit update and the reliance, it seems, on property sales for profits!
5-Mar-2018 – 26p – £104.8m – PER 358.1
Results For The 12 Months To End December 2017 – Revenue up 18.5% to $107.1m (2016: $90.4m), EPS is positive at 0.06¢ (2016: 0.27¢ loss per share).
The CEO describes this as a “turnaround year” (I guess on the basis EPS is positive for the first time) and says they are entering 2018 in a stronger position than last year. There’s not enough here for me at present.
28-Aug-2018 – 41.1p – £165.8m – PER 123.1
Interim Results For The 6 Months To End June 2018 – Revenue up 16.9% to $58.2m (H1 2017: $49.8m), Adjusted Loss reduced to $0.6m (H1 2017: $1.4m loss), Loss Per Share reduced to 0.35¢ (H1 2017: 0.66¢ loss per share) and there’s Cash and financial assets of $23.3m (31 December 2017: $24.0m).
Seems to be heading in the right direction but there’s still not enough here for me at present.
6-Mar-2019 – 46.5p – £188m – PER 102
Results For The 12 Months To End December 2018 – Looks good and due to a substantially higher year end Order book 2019 Revenue and EBITDA already expected to be ahead of market expectations.
Still seems to be heading in the right direction, I will be keeping an eye out for revised Broker notes here – Would be hopeful that PER looks more realistic now!
19-Aug-2019 – 43p – £187m – PER 66
Interim Results For The 6 Months To End June 2019 – Revenue, Gross Profit and Margin all down slightly, EPS 14c (-35c). Expects to report good growth for FY in-line with the Board’s expectations.
Still quite like this but feel more comfortable waiting to see FY results.
